10-decarboxymethylaclacinomycin A

10-decarboxymethylaclacinomycin A is a derivative of aclacinomycin A, an anthracycline antibiotic and antineoplastic agent. While aclacinomycin A (also known as aclarubicin) is well-characterized for its use in cancer therapy, particularly for acute myeloid leukemia and other hematologic malignancies, 10-decarboxymethylaclacinomycin A specifically refers to the compound where the carboxymethyl group at position 10 has been removed. This modification occurs during the biosynthesis of aclacinomycin by certain Streptomyces species[2]. The parent compound acts primarily as a dual inhibitor of topoisomerase I and II, interfering with DNA replication and transcription in rapidly dividing cells[1][4][5]. It also inhibits chymotrypsin-like activity of the proteasome and can induce histone eviction from chromatin upon intercalation[1][9]. The specific pharmacological properties or clinical applications of 10-decarboxymethylaclacinomycin A itself are not well documented in current literature; most available data pertain to its role as an intermediate or metabolite in the biosynthetic pathway leading to active anthracyclines like aclacinomycin A.

Other names

10-decarboxymethylaclacinomycin A